

ATP1A:ATP1B:FXVD binds cardiac glycos- ides

Jassal, B., Shoichet, BK.

European Bioinformatics Institute, New York University Langone Medical Center, Ontario Institute for Cancer Research, Oregon Health and Science University.

The contents of this document may be freely copied and distributed in any media, provided the authors, plus the institutions, are credited, as stated under the terms of [Creative Commons Attribution 4.0 International \(CC BY 4.0\) License](https://creativecommons.org/licenses/by/4.0/). For more information see our [license](https://reactome.org/licenses/).

19/04/2024

Introduction

Reactome is open-source, open access, manually curated and peer-reviewed pathway database. Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and cross-referenced to many bioinformatics databases. A system of evidence tracking ensures that all assertions are backed up by the primary literature. Reactome is used by clinicians, geneticists, genomics researchers, and molecular biologists to interpret the results of high-throughput experimental studies, by bioinformaticians seeking to develop novel algorithms for mining knowledge from genomic studies, and by systems biologists building predictive models of normal and disease variant pathways.

The development of Reactome is supported by grants from the US National Institutes of Health (P41 HG003751), University of Toronto (CFREF Medicine by Design), European Union (EU STRP, EMI-CD), and the European Molecular Biology Laboratory (EBI Industry program).

Literature references

- Fabregat, A., Sidiropoulos, K., Viteri, G., Forner, O., Marin-Garcia, P., Arnau, V. et al. (2017). Reactome pathway analysis: a high-performance in-memory approach. *BMC bioinformatics*, 18, 142. [↗](#)
- Sidiropoulos, K., Viteri, G., Sevilla, C., Jupe, S., Webber, M., Orlic-Milacic, M. et al. (2017). Reactome enhanced pathway visualization. *Bioinformatics*, 33, 3461-3467. [↗](#)
- Fabregat, A., Jupe, S., Matthews, L., Sidiropoulos, K., Gillespie, M., Garapati, P. et al. (2018). The Reactome Pathway Knowledgebase. *Nucleic Acids Res*, 46, D649-D655. [↗](#)
- Fabregat, A., Korninger, F., Viteri, G., Sidiropoulos, K., Marin-Garcia, P., Ping, P. et al. (2018). Reactome graph database: Efficient access to complex pathway data. *PLoS computational biology*, 14, e1005968. [↗](#)

Reactome database release: 88


This document contains 1 reaction ([see Table of Contents](#))

ATP1A:ATP1B:FXVD binds cardiac glycosides [↗](#)

Stable identifier: R-HSA-9684068

Type: binding

Compartments: extracellular region, plasma membrane



Cardiac glycosides are a class of organic compounds that increase the output force of the heart and increase its rate of contractions by inhibition of the cellular sodium-potassium ATPase pump (ATP1A1). Their beneficial medical uses are as treatments for congestive heart failure and cardiac arrhythmias. Cardiac glycosides are primarily derived from foxglove plants or from the venom of the cane toad *Bufo marinus*. Their toxicity prevents them from being widely used. Changes to heart inotropic and chronotropic activity results in multiple kinds of dysrhythmia and potentially fatal ventricular tachycardia. Different cardiac glycosides show different specificities towards sodium-potassium ATPase pump alpha isoforms (Hauck et al. 2009, Katz et al. 2010, Cherniavsky et al. 2015).

HIV-1 Tat is essential for HIV-1 replication. Tat must escape from the cell in order for it to activate the HIV-1 LTR promoter and facilitate HIV-1 viral replication. Tat utilises the cellular ATP1A1 pump for secretion out of cells. The cardiac glycosides ouabain, digoxin, digitoxin, acetyldigitoxin and deslanoside can all inhibit ATP1A1 (Smith 1984), impairing extracellular Tat release and blocking HIV-1 replication (Agostini et al. 2017).

Literature references

Smith, TW. (1984). The basic mechanism of inotropic action of digitalis glycosides. *J Pharmacol*, 15, 35-51. [↗](#)

Tasciotti, E., Fittipaldi, A., Agostini, S., Giacca, M., Ali, H., Vardabasso, C. et al. (2017). Inhibition of Non Canonical HIV-1 Tat Secretion Through the Cellular Na⁺/K⁺-ATPase Blocks HIV-1 Infection. *EBio-Medicine*, 21, 170-181. [↗](#)

Wittwer, T., Schwinger, RH., Wahlers, T., Bartz, M., Müller-Ehmsen, J., McDonough, AA. et al. (2009). Isoform specificity of cardiac glycosides binding to human Na⁺/K⁺-ATPase alpha1beta1, alpha2beta1 and alpha3beta1. *Eur. J. Pharmacol.*, 622, 7-14. [↗](#)

Garty, H., Cherniavsky Lev, M., Karlish, SJ. (2015). Cardiac glycosides induced toxicity in human cells expressing α1-, α2-, or α3-isoforms of Na-K-ATPase. *Am. J. Physiol., Cell Physiol.*, 309, C126-35. [↗](#)

Karlish, SJ., Bab-Dinitz, E., Tal, DM., Katz, A., Kapri-Pardes, E., Lifshitz, Y. et al. (2010). Selectivity of digitalis glycosides for isoforms of human Na,K-ATPase. *J. Biol. Chem.*, 285, 19582-92. [↗](#)

Editions

| | | |
|------------|------------------|---------------|
| 2020-04-20 | Authored, Edited | Jassal, B. |
| 2020-05-14 | Reviewed | Shoichet, BK. |